Israel · Delayed Price · Currency is ILS · Price in ILA Enlivex Therapeutics Statistics
Total Valuation
TLV:ENLV has a market cap or net worth of ILS 84.44 million. The enterprise value is 22.63 million.
| Market Cap | 84.44M |
| Enterprise Value | 22.63M |
Important Dates
The next estimated earnings date is Friday, November 28, 2025.
| Earnings Date | Nov 28, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 24.29M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +21.10% |
| Shares Change (QoQ) | +0.41% |
| Owned by Insiders (%) | 4.52% |
| Owned by Institutions (%) | 7.20% |
| Float | 21.78M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 1.32 |
| P/TBV Ratio | 1.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.51 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.53 |
Financial Position
The company has a current ratio of 6.41, with a Debt / Equity ratio of 0.03.
| Current Ratio | 6.41 |
| Quick Ratio | 6.20 |
| Debt / Equity | 0.03 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.04 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -55.02% and return on invested capital (ROIC) is -38.78%.
| Return on Equity (ROE) | -55.02% |
| Return on Assets (ROA) | -34.82% |
| Return on Invested Capital (ROIC) | -38.78% |
| Return on Capital Employed (ROCE) | -78.79% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | 71 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.00% in the last 52 weeks. The beta is 0.90, so TLV:ENLV's price volatility has been lower than the market average.
| Beta (5Y) | 0.90 |
| 52-Week Price Change | -34.00% |
| 50-Day Moving Average | 382.19 |
| 200-Day Moving Average | 385.00 |
| Relative Strength Index (RSI) | 54.11 |
| Average Volume (20 Days) | 35,066 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.32 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -51.15M |
| Pretax Income | -44.13M |
| Net Income | -44.13M |
| EBITDA | -49.90M |
| EBIT | -51.15M |
| Earnings Per Share (EPS) | -1.93 |
Balance Sheet
The company has 65.72 million in cash and 1.62 million in debt, giving a net cash position of 64.11 million.
| Cash & Cash Equivalents | 65.72M |
| Total Debt | 1.62M |
| Net Cash | 64.11M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 64.20M |
| Book Value Per Share | 2.69 |
| Working Capital | 60.63M |
Cash Flow
In the last 12 months, operating cash flow was -42.19 million and capital expenditures -279,652, giving a free cash flow of -42.47 million.
| Operating Cash Flow | -42.19M |
| Capital Expenditures | -279,652 |
| Free Cash Flow | -42.47M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TLV:ENLV does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.10% |
| Shareholder Yield | -21.10% |
| Earnings Yield | -52.26% |
| FCF Yield | -50.30% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |